With the high expression of VEGFR2 observed in mesothelioma cells, tyrosine kinase inhibitor therapies continue to be an attractive option for further research, especially when combined with PD-1/PD-L1 blocking agents. The gene discussed is CD274; the disease is mesothelioma.